Browse > Article
http://dx.doi.org/10.5483/BMBRep.2014.47.3.006

In vitro and in vivo application of anti-cotinine antibody and cotinine-conjugated compounds  

Kim, Hyori (Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine)
Yoon, Soomin (Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine)
Chung, Junho (Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine)
Publication Information
BMB Reports / v.47, no.3, 2014 , pp. 130-134 More about this Journal
Abstract
The combination of a high-affinity antibody to a hapten, and hapten-conjugated compounds, can provide an alternative to the direct chemical cross-linking of the antibody and compounds. An optimal hapten for in vitro use is one that is absent in biological systems. For in vivo applications, additional characteristics such as pharmacological safety and physiological inertness would be beneficial. Additionally, methods for cross-linking the hapten to various chemical compounds should be available. Cotinine, a major metabolite of nicotine, is considered advantageous in these aspects. A high-affinity anti-cotinine recombinant antibody has recently become available, and can be converted into various formats, including a bispecific antibody. The bispecific anti-cotinine antibody was successfully applied to immunoblot, enzyme immunoassay, immunoaffinity purification, and pre-targeted in vivo radioimmunoimaging. The anti-cotinine IgG molecule could be complexed with aptamers to form a novel affinity unit, and extended the in vivo half-life of aptamers, opening up the possibility of applying the same strategy to therapeutic peptides and chemical compounds.
Keywords
Affinity unit; Antibody; Cotinine; Hapten;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Deng, C., Pan, B. and O'Connor, O. A. (2013) Brentuximab vedotin. Clin. Cancer Res. 19, 22-27.   DOI   ScienceOn
2 Jain, N., Wierda, W., Ferrajoli, A., Wong, F., Lerner, S., Keating, M. and O'Brien, S. (2009) A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer 115, 4533-4539.   DOI   ScienceOn
3 Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J. H., Sliwkowski, M. X., Jacobson, F., Lutzker, S. G. and Burris, H. A. (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28, 2698-2704.   DOI   ScienceOn
4 Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blattler, W. A., Lambert, J. M., Chari, R. V., Lutz, R. J., Wong, W. L., Jacobson, F. S., Koeppen, H., Schwall, R. H., Kenkare-Mitra, S. R., Spencer, S. D. and Sliwkowski, M. X. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280-9290.   DOI   ScienceOn
5 Wakankar, A. A., Feeney, M. B., Rivera, J., Chen, Y., Kim, M., Sharma, V. K. and Wang, Y. J. (2010) Physicochemical stability of the antibody-drug conjugate Trastuzumab- DM1: changes due to modification and conjugation processes. Bioconjug. Chem. 21, 1588-1595.   DOI   ScienceOn
6 Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., Lu, Y., Meng, Y. G., Ng, C., Yang, J., Lee, C. C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S. D., Lee Wong, W., Lowman, H. B., Vandlen, R., Sliwkowski, M. X., Scheller, R. H., Polakis, P. and Mallet, W. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925-932.   DOI   ScienceOn
7 Dirksen, A., Hackeng, T. M. and Dawson, P. E. (2006) Nucleophilic catalysis of oxime ligation. Angew. Chem. Int. Edit. 45, 7581-7584.   DOI   ScienceOn
8 Li, X., Yang, J. and Rader, C. (2013) Antibody conjugation via one and two C-terminal selenocysteines. Methods 65, 133-138.
9 Popkov, M., Gonzalez, B., Sinha, S. C. and Barbas, C. F. (2009) Instant immunity through chemically programmable vaccination and covalent self-assembly. P. Natl. Acad. Sci. U. S. A. 106, 4378-4383.   DOI   ScienceOn
10 Ghesani, M., Belgraier, A. and Hasni, S. (2003) Carcinoembryonic antigen (CEA) scan in the diagnosis of recurrent colorectal carcinoma in a patient with increasing CEA levels and inconclusive computed tomographic findings. Clin. Nucl. Med. 28, 608-609.   DOI   ScienceOn
11 Capizzi, R. L. (2004) Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas. Trans. Am. Clin. Climatol. Assoc. 115, 255-272.
12 Jakubowski, H. (2002) Understanding biochemical dissociation constants: A temporal perspective. J. Chem. Educ. 79, 968-971.   DOI   ScienceOn
13 Goldenberg, D. M., Rossi, E. A., Sharkey, R. M., McBride, W. J. and Chang, C. H. (2008) Multifunctional antibodies by the dock-and-lock method for improved cancer Imaging and therapy by pretargeting. J. Nucl. Med. 49, 158-163.
14 Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J. H., Sliwkowski, M. X., Jacobson, F., Lutzker, S. G. and Burris, H. A. (2010) Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer. J. Clin. Oncol. 28, 2698-2704.   DOI   ScienceOn
15 Kontermann, R. E. (2012) Dual targeting strategies with bispecific antibodies. mAbs. 4, 182-197.   DOI   ScienceOn
16 Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., McBride, W. J., Sharkey, R. M. and Chang, C. H. (2006) Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. P. Natl. Acad. Sci. U. S. A. 103, 6841-6846.   DOI   ScienceOn
17 Chang, C. H., Rossi, E. A. and Goldenberg, D. M. (2007) The dock and lock method: A novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin. Cancer Res. 13, 5586s-5591s.   DOI   ScienceOn
18 Kim, I. and Huestis, M. A. (2006) A validated method for the determination of nicotine, cotinine, trans-3'-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. J. Mass Spectrom. 41, 815-821.   DOI   ScienceOn
19 Kosmas, C., Maraveyas, A., Gooden, C. S., Snook, D. and Epenetos, A. A. (1995) Anti-Chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal-antibody immunoconjugates for ovarian-cancer therapy. J. Nucl. Med. 36, 746-753.
20 Riah, O., Dousset, J. C., Courriere, P., Stigliani, J. L., Baziard-Mouysset, G. and Belahsen, Y. (1999) Evidence that nicotine acetylcholine receptors are not the main targets of cotinine toxicity. Toxicol. Lett. 109, 21-29.   DOI   ScienceOn
21 Moran, V. E. (2012) Cotinine : Beyond the expected, more than a biomarker of tobacco consumption. Front. Pharmacol. 3, 1-9.
22 Watanabe, N., Goodwin, D. A., Meares, C. F., Mctigue, M., Chaovapong, W., Ransone, C. M. and Renn, O. (1994) Immunogenicity in Rabbits and Mice of an Antibody-Chelate Conjugate - Comparison of (S) and (R) Macrocyclic Enantiomers and an Acyclic Chelating Agent. Cancer Res. 54, 1049-1054.
23 Kosmas, C., Snook, D., Gooden, C. S., Courtenayluck, N. S., Mccall, M. J., Meares, C. F. and Epenetos, A. A. (1992) Development of humoral immune-responses against a macrocyclic chelating agent (Dota) in cancer-patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res. 52, 904-911.
24 Baxter, A. B., Melnikoff, S., Stites, D. P. and Brasch, R. C. (1991) Immunogenicity of gadolinium-based contrast agents for magnetic-resonance-imaging - induction and characterization of antibodies in animals. Invest. Radiol. 26, 1035-1040.
25 Park, S., Lee, D. H., Park, J. G., Lee, Y. T. and Chung, J. (2010) A sensitive enzyme immunoassay for measuring cotinine in passive smokers. Clin. Chim. Acta. 411, 1238-1242.   DOI   ScienceOn
26 Park, S. (2012) Development of anti-cotinine antibody and its application to EIA and carrier for cotinine-conjugated molecule. Ph.D thesis, Seoul National University.
27 Wuellner, U., Gavrilyuk, J. I. and Barbas, C. F. (2010) Expanding the Concept of Chemically Programmable Antibodies to RNA Aptamers: Chemically Programmed Biotherapeutics. Angew. Chem. Int. Edit. 49, 5934-5937.   DOI   ScienceOn
28 Yoon, S., Kim, Y.-H., Kang, S. H., Kim, S.-K., Lee, H. K., Kim, H., Chung, J. and Kim, I.-H. (2013) Bispecific Her2 ${\times}$ cotinine antibody in combination with cotinine-(histidine) 2-iodine for the pre-targeting of Her2-positive breast cancer xenografts. J. Cancer Res. Clin. 140, 227-233.
29 Kim, H., Park, S., Lee, H. K. and Chung, J. (2013) Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification. Exp. Mol. Med. 45, e43.   DOI
30 Apte, R. S. (2008) Pegaptanib sodium for the treatment of age-related macular degeneration. Expert. Opin. Pharmaco. 9, 499-508.   DOI   ScienceOn
31 Park, S., Hwang, D. and Chung, J. (2012) Cotinine-conjugated aptamer/anti-cotinine antibody complexes as a novel affinity unit for use in biological assays. Exp. Mol. Med. 44, 554-561.   DOI   ScienceOn
32 Sharkey, R. M., Chang, C. H., Rossi, E. A., McBride, W. J. and Goldenberg, D. M. (2012) Pretargeting: taking an alternate route for localizing radionuclides. Tumor Biol. 33, 591-600.   DOI   ScienceOn
33 Sharkey, R. M., Rossi, E. A., McBride, W. J., Chang, C. H. and Goldenberg, D. M. (2010) Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin. Nucl. Med. 40, 190-203.   DOI   ScienceOn
34 Sharkey, R. M., Karacay, H., Chang, C. H., McBride, W. J., Horak, I. D. and Goldenberg, D. M. (2005) Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 19, 1064-1069.   DOI   ScienceOn
35 Karacay, H., Brard, P. Y., Sharkey, R. M., Chang, C. H., Rossi, E. A., McBride, W., Ragland, D. R., Horak, I. D. and Goldenberg, D. M. (2005) Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin. Cancer Res. 11, 7879-7885.   DOI   ScienceOn
36 Rabuka, D., Rush, J. S., deHart, G. W., Wu, P. and Bertozzi, C. R. (2012) Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat. Protoc. 7, 1052-1067.   DOI   ScienceOn
37 Axup, J. Y., Bajjuri, K. M., Ritland, M., Hutchins, B. M., Kim, C. H., Kazane, S. A., Halder, R., Forsyth, J. S., Santidrian, A. F., Stafin, K., Lu, Y. C., Tran, H., Seller, A. J., Biroce, S. L., Szydlik, A., Pinkstaff, J. K., Tian, F., Sinha, S. C., Felding-Habermann, B., Smider, V. V. and Schultz, P. G. (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. P. Natl. Acad. Sci. U. S. A. 109, 16101-16106.   DOI